Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Pyroptosis Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GSDMD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GSDMD Recombinant Protein (Full-Length & Truncated N-Terminal Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for caspase cleavage and pore-formation screening. |
View GSDMD Products |
| Gene Delivery | GSDMD Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to support cell-based pyroptosis assays. |
View GSDMD Products |
| Benchmark Ab | Anti-GSDMD Recombinant Antibody High-affinity positive control for Western Blot, IHC, and neutralization assays. |
View GSDMD Products |
| Validator | GSDMD siRNA Set For knockdown verification in primary macrophages and disease models. |
View GSDMD Products |
| Related Target A | NLRP3 Upstream inflammasome sensor driving GSDMD activation. Essential for pathway-level selectivity profiling. |
View NLRP3 Products |
| Related Target B | CASP1 Caspase-1 executioner protease. Crucial for in vitro GSDMD cleavage and activation assays. |
View CASP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cleavage Specificity Profiling | Recombinant GSDMD with sequence-verified caspase-1/4/5/11 cleavage sites. |
| Oligomerization & Pore-Formation Screening | High-purity active GSDMD-N domain (>95% by SDS-PAGE) for liposome leakage assays. |
| Lack of Cleavage-Resistant Controls | Mutant GSDMD (e.g., D275A cleavage-site mutant) available for negative control validation. |
| False Positives in Cell Assays | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live GSDMD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GSDMD therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum anti-inflammatory agents to selective pyroptosis inhibitors. As first-generation small molecule inhibitors enter early-phase clinical evaluation, the next wave of R&D is targeting GSDMD-N domain oligomerization and the preventing of pore formation. This selective inhibition holds immense promise for treating systemic inflammatory response syndrome (SIRS), sepsis, and autoimmune conditions without compromising apoptotic host defenses.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Covalent) | Novartis, Ventus Therapeutics | Sepsis, NASH, Gout, Inflammatory Bowel Disease | In vitro Caspase Cleavage Assay (Need high-purity full-length GSDMD) |
| Small Molecule (Non-covalent) | Startups, Academic Institutions | Neurodegenerative Diseases, MS | Pore-Formation Reconstitution (Need active GSDMD-N recombinant protein) |
| Gene Therapy (siRNA/shRNA) | Alnylam, Biotech Consortia | Acute Kidney Injury, Acute Pancreatitis | Target Knockdown Verification (Need verified siRNA sets and Lentivirus) |